ID   HTBOA
AC   CVCL_X939
SY   HTBoA
DR   CGH-DB; 378-2
DR   CGH-DB; 9353-4
DR   Wikidata; Q54896601
RX   PubMed=2448191;
RX   PubMed=3259199;
RX   PubMed=3593088;
RX   PubMed=9436037;
RX   PubMed=10457904;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
CC   Population: Japanese.
CC   Doubling time: 26 hours (PubMed=3259199); 28 hours (PubMed=3593088).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C4509; Ovarian undifferentiated carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 29-06-23; Version: 11
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=3259199; DOI=10.1016/0090-8258(88)90043-1;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Establishment and characterization of a human ovarian anaplastic
RT   carcinoma cell line.";
RL   Gynecol. Oncol. 30:35-43(1988).
//
RX   PubMed=3593088; DOI=10.1111/j.1447-0756.1987.tb00014.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "Cytological properties of human ovarian carcinoma cell lines.";
RL   Asia Oceania J. Obstet. Gynaecol. 13:79-86(1987).
//
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//